
Sierra Oncology SRRA
Quarterly report 2022-Q1
added 12-16-2023
Sierra Oncology Depreciation & Amortization 2011-2026 | SRRA
Annual Depreciation & Amortization Sierra Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 305 K | 238 K | 83 K | 111 K | 258 K | 197 K | 111 K | 12 K | 1 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 305 K | 1 K | 146 K |
Quarterly Depreciation & Amortization Sierra Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 92 K | - | 11 K | 11 K | 47 K | - | 191 K | 113 K | 55 K | - | 188 K | 126 K | 62 K | - | 26 K | 30 K | 29 K | - | 100 K | 100 K | 53 K | - | 45 K | 54 K | 52 K | - | 32 K | 26 K | 13 K | - | 3 K | 1 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 191 K | 1 K | 60.8 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbCellera Biologics
ABCL
|
18.4 M | $ 3.55 | -0.28 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Adagene
ADAG
|
723 K | $ 3.91 | -2.01 % | $ 220 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.79 | 0.04 % | $ 4.31 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
3.02 M | $ 6.39 | -3.62 % | $ 175 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
BioCardia
BCDA
|
84 K | $ 1.28 | 0.79 % | $ 27.1 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Atea Pharmaceuticals
AVIR
|
416 K | $ 6.13 | 1.32 % | $ 500 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
1.43 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 3.43 | -4.19 % | $ 7.46 B | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Catalyst Biosciences
CBIO
|
2.48 M | $ 11.1 | -4.15 % | $ 992 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
6.43 M | $ 14.51 | 1.04 % | $ 213 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
CNS Pharmaceuticals
CNSP
|
3.31 K | $ 2.26 | -7.76 % | $ 864 K | ||
|
AVEO Pharmaceuticals
AVEO
|
67 K | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.59 | -1.89 % | $ 16.3 M | ||
|
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.51 | - | $ 385 M | ||
|
Athira Pharma
ATHA
|
970 K | - | - | $ 269 M |